Bristol Myers Squibb announced on Aug. 10 that it will invest $2.3 billion to construct a new manufacturing campus in Houston, Texas, a project expected to create approximately 2,500 roles and accelerate the delivery of next-generation medicines.
The investment is part of Bristol Myers Squibb’s broader five-year, $40 billion commitment to American innovation and manufacturing made last year in response to President Donald Trump’s tariff threats. The company said the new campus will be modular, allowing for flexible adjustments in manufacturing capacity as needed.
The facility will offer multi-modal capabilities, enabling production of various types of medicines including small molecules, biologics, and antibody-drug conjugates. The planned Houston hub will span about 600,000 square feet with future expansion anticipated. Bristol Myers Squibb expects to initially hire nearly 500 people at the site and projects an additional 2,000 construction and indirect jobs related to the facility between 2027 and 2030.
According to the company release, Houston was selected after “an extensive, competitive evaluation of multiple markets in the Central and Eastern U.S.” Factors influencing this decision included the strength of the local life sciences workforce, available incentives, proximity to utilities and transportation infrastructure, as well as a business climate favorable for long-term growth.
U.S. Secretary of Commerce Howard Lutnick said in Monday's release, “We are making pharmaceuticals in America again thanks to President Trump’s America First Trade Agenda. Bristol Myers Squibb’s $2.3 billion investment in Texas will create hundreds of high-paying jobs and strengthen our pharmaceutical supply chains, ensuring America is never reliant on foreign sources for critical medicines.”
Last week saw speculation about a potential merger involving Bristol Myers Squibb; however, these rumors were debunked. Analysts had suggested such a deal could have helped address exclusivity losses for two top-selling drugs: Eliquis—developed with Pfizer—and Opdivo. Last year Eliquis generated $14.4 billion globally while Opdivo brought in $10 billion worldwide revenue; together they accounted for half of Bristol Myers Squibb's total revenue.
